MIRA Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MIRA Pharmaceuticals, Inc. (MIRA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $21.88 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $21.88K, a 95.53% decline year-over-year.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $21.59K, a 97.53% decline year-over-year.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $297.09K, a 10.44% increase year-over-year.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $489.57K, a 19.05% decline year-over-year.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.00M, a 212.57% increase from fiscal 2024.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.92M, a 24.70% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.55M, a 96.74% increase from fiscal 2022.
- MIRA Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.30M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.88K 10-Q · filed 2026-08-12 | $43.46K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $21.59K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $6.00M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $297.09K 10-Q · filed 2025-11-13 | $786.66K derived: sum of 2 quarters · filed 2026-08-12 | $1.66M derived: sum of 3 quarters · filed 2026-08-12 | $2.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $489.57K 10-Q · filed 2026-08-12 | $1.36M derived: sum of 2 quarters · filed 2026-08-12 | $1.91M derived: sum of 3 quarters · filed 2026-08-12 | $2.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $874.81K 10-Q · filed 2026-08-12 | $1.42M derived: sum of 2 quarters · filed 2026-08-12 | $1.69M derived: sum of 3 quarters · filed 2026-08-12 | $2.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2024-12-31 | $546.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $815.79K derived: sum of 2 quarters · filed 2026-03-31 | $1.42M derived: sum of 3 quarters · filed 2026-03-31 | $1.92M 10-K · filed 2026-03-31 |
| 2024-09-30 | $269.01K 10-Q · filed 2025-11-13 | $873.82K derived: sum of 2 quarters · filed 2025-11-13 | $1.37M 10-Q · filed 2024-11-12 | $1.59M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $604.80K 10-Q · filed 2025-11-13 | $1.11M 10-Q/A · filed 2024-08-16 | $1.32M derived: sum of 3 quarters · filed 2025-11-13 | $2.77M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | $500.21K 10-Q · filed 2025-11-13 | $714.02K derived: sum of 2 quarters · filed 2025-11-13 | $2.17M derived: sum of 3 quarters · filed 2025-11-13 | $2.90M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | $213.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.67M derived: sum of 2 quarters · filed 2025-03-28 | $2.40M derived: sum of 3 quarters · filed 2025-03-28 | $2.55M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.45M 10-Q · filed 2024-11-12 | $2.19M derived: sum of 2 quarters · filed 2024-11-12 | $2.34M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $737.20K 10-Q/A · filed 2024-08-16 | $737.20K 10-Q/A · filed 2024-08-16 | ||
| 2023-03-31 | $147.80K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $1.30M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $147.80K 10-Q · filed 2023-11-13 | $1.15M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $1.00M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |